NCT01693783 - Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2012

Primary Completion Date

March 18, 2021

Study Completion Date

November 24, 2021

Conditions

Cervical AdenocarcinomaCervical Squamous Cell CarcinomaHuman Papillomavirus InfectionRecurrent Cervical CarcinomaStage IVA Cervical Cancer AJCC v6 and v7Stage IVB Cervical Cancer AJCC v6 and v7

Interventions

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (13)

19111

Fox Chase Cancer Center, Philadelphia

60637

University of Chicago Comprehensive Cancer Center, Chicago

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 1L3

BC Cancer Research Centre, Vancouver

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital and Cancer Center-General Campus, Ottawa

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH